|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PDHB |
Gene summary for PDHB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PDHB | Gene ID | 5162 |
| Gene name | pyruvate dehydrogenase E1 subunit beta | |
| Gene Alias | PDHBD | |
| Cytomap | 3p14.3 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | P11177 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5162 | PDHB | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.41e-04 | 7.03e-02 | 0.0155 |
| 5162 | PDHB | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.25e-08 | 3.81e-01 | -0.0811 |
| 5162 | PDHB | HTA11_78_2000001011 | Human | Colorectum | AD | 2.53e-09 | 2.77e-01 | -0.1088 |
| 5162 | PDHB | HTA11_347_2000001011 | Human | Colorectum | AD | 4.81e-15 | 3.41e-01 | -0.1954 |
| 5162 | PDHB | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.26e-12 | 3.44e-01 | -0.059 |
| 5162 | PDHB | HTA11_2992_2000001011 | Human | Colorectum | SER | 6.20e-04 | 3.56e-01 | -0.1706 |
| 5162 | PDHB | HTA11_546_2000001011 | Human | Colorectum | AD | 2.85e-03 | 1.37e-01 | -0.0842 |
| 5162 | PDHB | HTA11_866_3004761011 | Human | Colorectum | AD | 3.84e-06 | 2.11e-01 | 0.096 |
| 5162 | PDHB | HTA11_6801_2000001011 | Human | Colorectum | SER | 5.10e-03 | 3.61e-01 | 0.0171 |
| 5162 | PDHB | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.86e-03 | 1.29e-01 | 0.0674 |
| 5162 | PDHB | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.83e-08 | 3.83e-01 | 0.294 |
| 5162 | PDHB | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.37e-06 | 7.79e-01 | 0.3487 |
| 5162 | PDHB | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.29e-06 | 2.41e-01 | 0.281 |
| 5162 | PDHB | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.22e-08 | 3.52e-01 | 0.3859 |
| 5162 | PDHB | LZE4T | Human | Esophagus | ESCC | 2.46e-13 | 2.51e-01 | 0.0811 |
| 5162 | PDHB | LZE8T | Human | Esophagus | ESCC | 1.99e-05 | 8.24e-02 | 0.067 |
| 5162 | PDHB | LZE20T | Human | Esophagus | ESCC | 3.77e-02 | -5.29e-02 | 0.0662 |
| 5162 | PDHB | LZE22T | Human | Esophagus | ESCC | 1.13e-04 | 1.36e-01 | 0.068 |
| 5162 | PDHB | LZE24T | Human | Esophagus | ESCC | 4.27e-17 | 3.40e-01 | 0.0596 |
| 5162 | PDHB | LZE6T | Human | Esophagus | ESCC | 4.24e-04 | 6.32e-02 | 0.0845 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0046390111 | Skin | cSCC | ribose phosphate biosynthetic process | 79/4864 | 190/18723 | 1.86e-06 | 3.10e-05 | 79 |
| GO:000911724 | Skin | cSCC | nucleotide metabolic process | 173/4864 | 489/18723 | 2.03e-06 | 3.35e-05 | 173 |
| GO:0072521112 | Skin | cSCC | purine-containing compound metabolic process | 150/4864 | 416/18723 | 2.88e-06 | 4.54e-05 | 150 |
| GO:0009259112 | Skin | cSCC | ribonucleotide metabolic process | 138/4864 | 385/18723 | 1.00e-05 | 1.30e-04 | 138 |
| GO:0006163112 | Skin | cSCC | purine nucleotide metabolic process | 140/4864 | 396/18723 | 1.93e-05 | 2.27e-04 | 140 |
| GO:0009260111 | Skin | cSCC | ribonucleotide biosynthetic process | 73/4864 | 182/18723 | 2.01e-05 | 2.36e-04 | 73 |
| GO:0009150112 | Skin | cSCC | purine ribonucleotide metabolic process | 131/4864 | 368/18723 | 2.42e-05 | 2.76e-04 | 131 |
| GO:007252218 | Skin | cSCC | purine-containing compound biosynthetic process | 78/4864 | 200/18723 | 3.44e-05 | 3.74e-04 | 78 |
| GO:190129310 | Skin | cSCC | nucleoside phosphate biosynthetic process | 95/4864 | 256/18723 | 5.21e-05 | 5.31e-04 | 95 |
| GO:000916510 | Skin | cSCC | nucleotide biosynthetic process | 94/4864 | 254/18723 | 6.40e-05 | 6.25e-04 | 94 |
| GO:0009152111 | Skin | cSCC | purine ribonucleotide biosynthetic process | 67/4864 | 169/18723 | 6.60e-05 | 6.43e-04 | 67 |
| GO:000616418 | Skin | cSCC | purine nucleotide biosynthetic process | 73/4864 | 191/18723 | 1.28e-04 | 1.17e-03 | 73 |
| GO:000599610 | Skin | cSCC | monosaccharide metabolic process | 85/4864 | 257/18723 | 6.43e-03 | 3.14e-02 | 85 |
| GO:00060844 | Skin | cSCC | acetyl-CoA metabolic process | 16/4864 | 35/18723 | 9.09e-03 | 4.16e-02 | 16 |
| GO:000600610 | Skin | cSCC | glucose metabolic process | 66/4864 | 196/18723 | 9.75e-03 | 4.32e-02 | 66 |
| GO:0009060112 | Thyroid | PTC | aerobic respiration | 126/5968 | 189/18723 | 7.07e-23 | 1.78e-20 | 126 |
| GO:0006091112 | Thyroid | PTC | generation of precursor metabolites and energy | 252/5968 | 490/18723 | 8.24e-20 | 1.13e-17 | 252 |
| GO:0045333112 | Thyroid | PTC | cellular respiration | 140/5968 | 230/18723 | 9.60e-20 | 1.26e-17 | 140 |
| GO:0015980111 | Thyroid | PTC | energy derivation by oxidation of organic compounds | 176/5968 | 318/18723 | 2.67e-18 | 2.90e-16 | 176 |
| GO:001969327 | Thyroid | PTC | ribose phosphate metabolic process | 176/5968 | 396/18723 | 8.28e-08 | 1.70e-06 | 176 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
| hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
| hsa00620 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
| hsa00020 | Colorectum | AD | Citrate cycle (TCA cycle) | 20/2092 | 30/8465 | 1.43e-06 | 1.77e-05 | 1.13e-05 | 20 |
| hsa00010 | Colorectum | AD | Glycolysis / Gluconeogenesis | 34/2092 | 67/8465 | 3.63e-06 | 4.34e-05 | 2.77e-05 | 34 |
| hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
| hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
| hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
| hsa054151 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
| hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
| hsa006201 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
| hsa000201 | Colorectum | AD | Citrate cycle (TCA cycle) | 20/2092 | 30/8465 | 1.43e-06 | 1.77e-05 | 1.13e-05 | 20 |
| hsa000101 | Colorectum | AD | Glycolysis / Gluconeogenesis | 34/2092 | 67/8465 | 3.63e-06 | 4.34e-05 | 2.77e-05 | 34 |
| hsa040661 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
| hsa052301 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
| hsa049221 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
| hsa054152 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
| hsa006202 | Colorectum | SER | Pyruvate metabolism | 22/1580 | 47/8465 | 9.62e-06 | 1.33e-04 | 9.67e-05 | 22 |
| hsa000202 | Colorectum | SER | Citrate cycle (TCA cycle) | 16/1580 | 30/8465 | 2.06e-05 | 2.74e-04 | 1.99e-04 | 16 |
| hsa049222 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PDHB | SNV | Missense_Mutation | novel | c.947N>C | p.Asn316Thr | p.N316T | P11177 | protein_coding | deleterious(0.01) | benign(0.259) | TCGA-E2-A15A-06 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| PDHB | SNV | Missense_Mutation | c.985G>A | p.Asp329Asn | p.D329N | P11177 | protein_coding | deleterious(0.01) | probably_damaging(0.942) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PDHB | SNV | Missense_Mutation | novel | c.445N>A | p.Gly149Ser | p.G149S | P11177 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| PDHB | SNV | Missense_Mutation | novel | c.959N>T | p.Ala320Val | p.A320V | P11177 | protein_coding | deleterious(0) | possibly_damaging(0.829) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PDHB | SNV | Missense_Mutation | c.157N>A | p.Val53Ile | p.V53I | P11177 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| PDHB | SNV | Missense_Mutation | novel | c.787N>C | p.Cys263Arg | p.C263R | P11177 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| PDHB | SNV | Missense_Mutation | c.794N>C | p.Val265Ala | p.V265A | P11177 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-A5-A0GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PDHB | SNV | Missense_Mutation | novel | c.839N>C | p.Glu280Ala | p.E280A | P11177 | protein_coding | tolerated(0.33) | benign(0.019) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PDHB | SNV | Missense_Mutation | novel | c.970N>T | p.Arg324Cys | p.R324C | P11177 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PDHB | SNV | Missense_Mutation | novel | c.345N>A | p.Phe115Leu | p.F115L | P11177 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5162 | PDHB | ENZYME | CPI-613 | |||
| 5162 | PDHB | ENZYME | DEXLIPOTAM |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |